Bibliography
Found 69 results
Filters: Author is Ellis, R J [Clear All Filters]
Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019 ;33(3):475-481.
COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV. Journal of Acquired Immune Deficiency Syndromes . 2019 ;81.
. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.
Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society [Internet]. 2019 . Available from: https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1355617719000018
Nuclear-Mitochondrial interactions influence susceptibility to HIV-associated neurocognitive impairment. Mitochondrion. 2019 ;46:247-255.
. HIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex. Pain Med. 2017 ;18(3):428-440.
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. J Neurovirol. 2014 ;20(6):603-11.
Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count. Journal of NeuroVirology [Internet]. 2014 ;20(4):371-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24817145
. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res. 2014 ;218(1-2):201-8.
. Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer. Journal of NeuroVirology [Internet]. 2013 ;19(1):89-101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23341224
Alterations in the levels of vesicular trafficking proteins involved in HIV replication in the brains and CSF of patients with HIV-associated neurocognitive disorders. Journal of Neuroimmune Pharmacology [Internet]. 2013 ;8(5):1197-1209. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24292993
. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.
Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.
Global NeuroAIDS roundtable. J Neurovirol. 2013 ;19(1):1-9.
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology. 2013 ;80(15):1415-23.
. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol. 2012 ;26(6):894-908.
Diagnosing symptomatic HIV-associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc. 2012 ;18(1):79-88.
Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012 ;78(7):485-92.
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 ;75(23):2087-96.
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. Journal of Neurovirology [Internet]. 2009 ;15:360-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20175693